Mechanism of action
As a synthetic opioid receptor agonist, Loperamide selectively binds to opioid receptors in the intestinal wall. The drug inhibits the release of acetylcholine and prostaglandins, which leads to a decrease in propulsive intestinal motility, an increase in transit time of contents, and an increase in anal sphincter tone.
The most important pharmacokinetic factor is resistance to penetration across the blood-brain barrier (BBB). The ATP-dependent transport protein P-glycoprotein acts as an efflux pump, actively pumping drug molecules out of brain tissue back into the bloodstream. This completely prevents the development of central opioid effects (euphoria, respiratory depression).
Pharmacological effects
The main pharmacological effect is a potent antidiarrheal action, similar to that of codeine, but achieved exclusively through a peripheral mechanism. The drug reduces intestinal peristalsis, increases water and salt absorption, and helps normalize stool in diarrheal syndromes of various origins.
Indications for use
The primary indication is the symptomatic treatment of acute and chronic diarrhea. The drug is used as part of combination therapy to rapidly reduce the frequency and liquidity of stools when it is necessary to limit the motor activity of the gastrointestinal tract.
Side effects and interactions
Tolerability of the drug at therapeutic doses is favorable, with adverse reactions being rare (in 1–10% of patients). Headache, nausea, constipation, and dizziness may occur.
It is extremely dangerous to co-administer the drug with P-glycoprotein inhibitors (e.g., verapamil, quinidine). Blockade of this transport protein abolishes the brain's barrier protection: loperamide crosses the BBB unhindered, which threatens the development of severe central nervous system adverse reactions. In addition, the drug's absorption is reduced when used concurrently with antacids, calcium salts, and prokinetics (metoclopramide).
Prescription details
The drug is available as tablets and capsules of 0.002 g. According to reference data, the standard single dose is 0.002–0.004 g orally, while the maximum daily dose (MDD) is limited to 0.016 g. The drug does not cause tolerance or drug dependence when therapeutic dosages are observed.
Briefly: answers to topical questions
Which P-glycoprotein inhibitors are dangerous to combine with loperamide?
Loperamide is dangerous to combine with the following P-glycoprotein inhibitors:
- Verapamil (Verapamil) — a transport protein blocker;
- Quinidine — an efflux pump inhibitor.
Blockade of P-glycoprotein leads to the penetration of loperamide across the blood-brain barrier into brain tissue. This creates a high risk of severe central nervous system adverse reactions, including respiratory depression and euphoria.
What gastrointestinal side effects can loperamide cause?
Loperamide may cause the following gastrointestinal side effects:
- Constipation — a result of reduced propulsive peristalsis;
- Nausea — a potential dyspeptic symptom;
- Diarrhea — a rare adverse reaction.
Overall, the drug is well tolerated; side effects are rare and occur in only 1–10% of patients.
Loperamide is a "shovel" for the intestine: it slows down peristalsis and locks down the stool, while P-glycoprotein acts as a barrier, keeping it out of the head.
Class and exam questions
What is the pharmacological profile of loperamide?
Loperamide is a peripherally acting opioid receptor agonist that reduces intestinal motility and is used as an antidiarrheal agent.
Why doesn't loperamide cause central opioid effects?
The drug does not cross the blood-brain barrier because it serves as a substrate for P-glycoprotein, an ATP-dependent transport protein that pumps it back into the blood.
What does the combination of loperamide with verapamil lead to?
Verapamil inhibits P-glycoprotein, leading to loperamide crossing the BBB and a high risk of severe CNS side effects.
What is the maximum daily oral dose of loperamide?
The maximum daily dose (MDD) of the drug is 0.016 g, with a standard single dose of 0.002–0.004 g.
What else to study on this topic
- The role of P-glycoprotein in the pharmacokinetics of other substrates (digoxin, cyclosporine)
- Strategies for overcoming the blood-brain barrier using nanoparticles
- Comparative analysis of synthetic opioid receptor agonists (loperamide and nufenoxole)
- Mechanisms of drug interactions of efflux transporter blockers in the CNS
- Clinical pharmacology of antidiarrheal agents and their differences from laxatives
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Loperamide" and 5,304 other pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.